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Abstract
Objectives. Gastrointestinal side-effects caused by mycophenolic acid (MPA) are frequent in liver transplant recipients, and in
these cases a switch from two to three daily doses is usually recommended. However, a limited sampling strategy for the
estimation of MPA area under the curve from 0 to 8 hours (AUC(0–8h)) has not been made.
Design and methods. In 22 liver transplant patients who were administered MPA three times daily, the trapezoidal extrapolated
MPA AUC(0–8h) values using a sampling time from 0 to 2 hours were calculated.
Results. A tentative therapeutic range for MPA AUC(0–8h) of about 20–40 mg.h/mL is proposed, and in the 13 patients with
supratherapeutic values the total leukocyte blood count was signiﬁcantly lower than in the 9 patients with AUC(0–8h) £ 40 mg.h/
mL (P < 0.001). Signiﬁcant negative correlations were found between the total leukocyte blood count and the MPA trough
levels (r = 0.458; P < 0.05), AUC(0–8h) (r = 0.479; P < 0.05), and AUC(0–2h) (r = 0.437; P < 0.05). A signiﬁcant correlation
was found between the trapezoidal extrapolated AUC(0–8h) and trapezoidal AUC(0–2h) results (r = 0.850; P < 0.001).
Conclusions. The trapezoidal extrapolated AUC(0–8h), and possibly trapezoidal AUC(0–2h), may be useful for routine therapeutic
MPA monitoring in liver transplant recipients in which the dosing frequency is increased from twice to three times a day.
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Introduction
Mycophenolic acid (MPA) is the active constituent of
mycophenolate mofetil (MMF), which is a common
component of the immunosuppressive regimens fol-
lowing transplantation. With the increasing use of
MPA, the need for more accurate drug dosage has
become evident, and the current scientiﬁc evidence
for its concentration-controlled dosing in solid organ
transplantation has been recently reviewed (1). MPA
is usually administered in two daily doses, and the full
MPA area-under-the-curve (AUC) from0to 12hours
(AUC(0–12h)) is considered the best measure of overall
drug exposure; however, it is an impractical monitor-
ing strategy for everyday clinical use (1). Limited
sampling from the ﬁrst few hours post-dose makes
it possible to predict the full MPA AUC, and the most
promising results to date regarding therapeutic MPA
monitoring come from these limited sampling strat-
egies (1,2). The majority of proposed limited-sam-
pling strategies for estimating MPA AUC(0–12h) was
developed for kidney transplant recipients, and few
algorithms for liver transplant patients are included
by Bruchet and Emson in their recent systematic
review (3).
The side-effects of MPA mainly involve the
gastrointestinal tract (diarrhoea, nausea, abdominal
discomfort) and bone-marrow (leucopenia, thrombo-
cytopenia), but do not normally require the immu-
nosuppressive agent to be changed (1,4). Diarrhoea
and vomiting have a high prevalence among liver
transplant patients receiving MMF orally (1,5), and
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DOI: 10.3109/03009734.2010.523801these side-effects usually respond to dose reduction or
switching from two to three divided daily doses (5).
However, at least to our knowledge, a simpliﬁed
sampling time proﬁle for the estimation of MPA
AUC from 0 to 8 hours (AUC(0–8h)) in liver transplant
recipients treated with MMF three times daily has not
been previously reported.
The routine application of abbreviated-sampling
time strategies to estimate MPA AUC is feasible, if
all samples can be taken within a 2-hour window (6).
The aim of our study was to establish a trapezoidal
extrapolated AUC(0–8h) using a sampling time of 0 to
2 hours for the therapeutic MPA monitoring in liver
transplant recipients, who were administered MPA
every 8 hours due to gastrointestinal drug side-
effects using the typical daily dose. The results of
the trapezoidal extrapolated AUC(0–8h) simpliﬁed
strategy were compared with those of the trapezoidal
AUC from 0 to 2 hours (AUC(0–2h)), which has been
recently used for therapeutic drug monitoring of MPA
administered in two daily doses to liver transplant
patients (7).
Patients and methods
MPA levels were monitored in 22 maintenance liver
transplant recipients (17 males and 5 females) with a
mean (± SEM) age of 58.1 ± 2.4 years, receiving daily
oral treatment with MMF (CellCept
 , Hoffman La
Roche, Basel, Switzerland) at an 8-hour interval in
monotherapy (n = 6), or together with cyclosporin
(n = 4) or tacrolimus (n = 12). In all of the cases,
the reason for switching the MMF dosage from two to
three divided daily doses was due to MPA side-
effects involving the gastrointestinal tract (diarrhoea
and nausea). After the MPA steady-state was achieved,
blood samples were taken in BD Vacutainer
  tubes
containing K3EDTA as anticoagulant, immediately
before the next dose of MMF (C0), and half an
hour (C0.5) and 2 hours (C2) post-dose. This study
was carried out according to the good practice rules for
investigations in humans of the Conselleria de Sani-
dade (Regional Ministry of Health) of the Xunta de
Galicia, Spain.
MPA plasma concentrations were determined in
duplicate using the EMIT
  2000 Mycophenolic Acid
Assay in a Dimension
  Xpand Plus analyzer (Siemens
Healthcare Diagnostics Inc., Newark, DE, USA). In
accordance with the procedure developed in kidney
transplant recipients by Hale et al. (8), the AUC from
0 to 2 hours (AUC(0–2h)) was calculated using the
linear trapezoidal rule, and the AUC values were
extrapolated from 0 to 8 hours (AUC(0–8h)) consid-
ering the mathematically estimated concentrations at
6( C 6) and 8 (C8) hours. According to the character-
istics of the MPA concentration-time proﬁles in
liver transplant recipients (9), the C6 and C8
concentrations were calculated using the expressions:
C6 = 1.25C0 + 0.15, and C8 = C0. The blood counts of
total, polymorphonuclear (PMN) and mononuclear
(MN) leukocytes, and platelets were carried out in an
Advia
  2120 Hematology System from Siemens
Healthcare Diagnostics Inc.
Statistical analysis of the data was carried out using
the Microsoft Excel (v. 5.0) package, and the
Kolmogorov-Smirnov test was applied to check for
normality. MPA levels and AUC data had Gaussian
distributions, and consequently Pearson’s correlation
coefﬁcient, linear regression, and Sy.x as measure of
dispersion, were used. In other cases the Spearman’s
correlation coefﬁcient was used. The results are
expressed as mean ± SEM (median).
Results
The generally considered therapeutic window for
MPA AUC(0–12h) is 30–60 mg.h/mL (10,11), and
consequently, for the maintenance of an analogous
daily drug exposure (cumulative 24 hours AUC), a
tentative therapeutic interval for MPA AUC(0–8h) of
around 20–40 mg.h/mL may be proposed.
The relationship between the trapezoidal extrapo-
lated MPA AUC(0–8h) and the trapezoidal AUC(0–2h)
values is shown in Figure 1, and, in accordance
with the linear regression equation, the estimated
therapeutic range for AUC(0–2h) may be about
5–14 mg.h/mL. In the 22 patients studied the mean
trapezoidal extrapolated MPA AUC(0–8h) was 49.7 ±
4.9 mg.h/mL (range 16.5–92.2 mg.h/mL), and in
13 cases the values were supratherapeutic (>40 mg.
h/mL). For the MPA trapezoidal AUC(0–2h) a mean
value of 18.9 ± 2.0 mg.h/mL (range 7.3–37.9 mg.h/mL)
was obtained, and also in 13 cases the values were
supratherapeutic (>14 mg.h/mL). However, a modest
concordance was observed in the classiﬁcation of
AUC(0–2h) and AUC(0–8h) values as subtherapeutic,
therapeutic or supratherapeutic (Figure 1).
Signiﬁcant correlations were found between the
trapezoidal extrapolated MPA AUC(0–8h) and C0
(AUC(0–8h) = 9.79C0 + 16.24; r = 0.909; P < 0.001;
Sy.x=9.9mg.h/mL),C0.5(AUC(0–8h)=1.77C0.5+27.38;
r = 0.636; P < 0.01; Sy.x = 18.3 mg.h/mL), and C2
(AUC(0–8h) = 4.42C2 + 18.20; r = 0.753; P < 0.001;
Sy.x = 15.6 mg.h/mL). Similarly, signiﬁcant correla-
tions were also found between the trapezoidal
MPA AUC(0–2h) and C0 (AUC(0–2h) = 3.03C0 +8 . 5 0 ;
r = 0.689; P < 0.001; Sy.x = 6.99 mg.h/mL), C0.5
(AUC(0–2h) = 1.06C0.5 +5 . 4 1 ;r = 0.939;
48 B. Marcos et al.P < 0.001; Sy.x = 3.31 mg.h/mL), and C2
(AUC(0–2h) = 0.99C2 + 11.78; r = 0.415; P » 0.05;
Sy.x = 8.78 mg.h/mL).
With respect to the 13 cases with trapezoidal extrap-
olated MPA AUC(0–8h) > 40 mg.h/mL, in the 9 cases
with trapezoidal extrapolated MPA AUC(0–8h) £ 40 mg.
h/mL the MPA C0 level (1.7 ± 0.2 mg/mL (1.9 mg/mL)
versus 4.9 ± 0.5 mg/mL (4.4 mg/mL)) was signiﬁcantly
lower (P < 0.001), and the total leukocyte blood count
(7504 ± 687/mL( 7 6 0 0 / mL) versus 5131 ± 438/mL
(4930/mL)) was signiﬁcantly higher (P < 0.05). How-
ever,forthe blood count ofPMN,and MNleukocytes,
and platelets, the differences were not signiﬁcant.
Table I shows the correlation coefﬁcients of the blood
count of total,PMN, and MNleukocytes,and platelets
with the MPA C0,C 0.5,a n dC 2 levels, and AUC(0–8h)
and AUC(0–2h).
Discussion
It has been suggested that concentrations of MPA in
the immediate post-dose period may not accurately
correlate to total drug exposure, because these con-
centration–time points do not capture a second peak
concentration due to the drug reabsorption into
circulation after its biliary excretion (2). However,
substantial research has been conducted to develop
limited-sampling strategies to estimate MPA AUC in
kidney, heart, liver, and lung transplantation, and it
seems that concentrations in the immediate post-
dose period can accurately predict total MPA
AUC(0–12h) (3).
The clinical usefulness of the MMF original dosing
protocol change from two to three times daily, over-
coming the disadvantage of short MPA half-life and
improving immunosuppression in haematopoietic cell
transplantation, has been the subject of discussion
(12–14). With respect to solid organ transplant reci-
pients, treating physicians usually increase the dosing
frequency to three times a day if MPA gastrointestinal
side-effects are present (5). In these clinical condi-
tions, it may be important to have a simpliﬁed strategy
available for the MPA AUC(0–8h) estimation applica-
ble to the routine drug exposure monitoring.
At present, the selection of appropriate target
ranges for MPA AUC(0–12h) is challenging, as the
range of 30–60 mg.h/mL was based on the use of
MMF in the early post-renal transplant period with
concomitant cyclosporin (3). Similarly, the analytical
method used for the MPA determination should be
considered, as the results produced by the enzyme
multiplied enzyme immunoassay (EMIT) are higher
than those of the chromatographic-based techniques,
because the antibody used in the immunoassay has
cross-reactivity with the pharmacologically active
MPA acyl glucuronide metabolite (1,3). In any
case, we considered the therapeutic range of 30–60
mg.h/mL for MPA AUC(0–12h) due to its wide accep-
tance (7,10–12,15,16). Consequently, for the main-
tenance of an analogous daily drug exposure, a
therapeutic range of 20–40 mg.h/mL may be proposed
for the MPA AUC(0–8h). The increase of the MMF
dosing frequency could statistically maintain higher
MPA trough levels and steady-state concentrations
(AUC/dosing interval) (13), and in 13 cases (59%)
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Figure 1. Correlation and regression between the trapezoidal
mycophenolic acid (MPA) AUC(0–2h) and trapezoidal extrapolated
MPA AUC(0–8h) in liver transplant recipients treated three times
daily with mycophenolate mofetil (MMF) in monotherapy (D), or
co-medicated with cyclosporin (.) or tacrolimus (*). The dashed
lines correspond to the tentative therapeutic ranges for MPA
AUC(0–2h) and AUC(0–8h).
Table I. Correlation coefﬁcients of the blood count of total,
polymorphonuclear (PMN), and mononuclear (MN) leukocytes,
and platelets with mycophenolic acid levels and AUC(0–2h) and
AUC(0–8h) (n = 22).
Total leukocytes PMN MN Platelets
C0h 0.458
(P = 0.032)
0.399
(P = 0.066)
0.449
(P = 0.036)
0.197
(P = 0.379)
C0.5h 0.364
(P = 0.096)
0.201
(P = 0.371)
0.328
(P = 0.136)
0.351
(P = 0.109)
C2h 0.312
(P = 0.157)
0.374
(P = 0.086)
0.028
(P = 0.903)
0.020
(P = 0.931)
AUC(0–2h) 0.437
(P = 0.042)
0.324
(P = 0.141)
0.295
(P = 0.183)
0.238
(P = 0.286)
AUC(0–8h) 0.479
(P = 0.024)
0.419
(P = 0.052)
0.299
(P = 0.176)
0.205
(P = 0.360)
Mycophenolic acid area under the curve from 0 to 8 hours 49the trapezoidal extrapolated MPA AUC(0–8h) values
were supratherapeutic, suggesting the suitability of a
drug dosage adjustment.
A modest concordance was found between subther-
apeutic, therapeutic, and supratherapeutic AUC(0–8h)
and AUC(0–2h) values (Figure 1). Co-administration of
other immunosuppressant agents may inﬂuence MPA
exposure, as is clearly shown for cyclosporin with
30%–40% lower dose-normalized MPA exposure
(1). However, in the group of patients studied, con-
comitant cyclosporin administration does not appear
to modify signiﬁcantly the relationship between the
MPA AUC(0–2h) and AUC(0–8h) (Figure 1).
Therapeutic monitoring of MPA in liver transplan-
tation has predominantly used the trough concentra-
tion (C0), although additional AUC data exist in some
studies, suggesting an acceptable correlation of C0
with AUC(0–12h) (1) and AUC(0–2h) (7). In our study,
the higher correlation coefﬁcients were found
between MPA C0 and AUC(0–8h) (r = 0.909;
P < 0.001), and C0.5 and AUC(0–2h) (r = 0.939;
P < 0.001).
It has been reported that in liver transplant recipi-
ents treated with two daily doses of MMF, the
MPA pharmacokinetic parameters, C0,C max, and
AUC(0–12h), were signiﬁcantly higher in patients
with side-effects than in those with an uneventful
outcome (16). However, Shin et al. (7) recently
described no signiﬁcant relationships among MPA
C0 levels or AUC(0–2h) with the degree of leucopenia,
diarrhoea, or infection. In our group of patients with
MPA AUC(0–8h) >40 mg.h/mL, the blood count of
total leukocytes was signiﬁcantly lower than in the
group of patients with AUC(0–8h) £40 mg.h/mL
(P < 0.05). Similarly, signiﬁcant negative correlations
between the blood count of total leukocytes, with the
MPA trough levels, AUC(0–8h), and AUC(0–2h) were
found (Table I).
Regional concentrations of MPA in gastrointestinal
epithelial cells, not reﬂecting systemic exposure, may
contribute to undesirable gastrointestinal events (16).
In accordance with Brunet et al. (17), gastrointestinal
side-effects of MPA in liver transplant recipients were
associated with high drug levels obtained 40 min after
dose, but not with AUC(0–12h) or C0. These results
may explain the beneﬁcial effect of the increase of
MPA dosing frequency, maintaining an analogous
daily drug exposure, on the diarrhoea, nausea, and
vomiting. Trapezoidal extrapolated AUC(0–8h) may be
used for the routine MPA exposure monitoring in
liver transplant recipients treated with this drug three
times daily. Further studies on a larger number of
transplant patients are necessary for the evaluation
of the clinical usefulness of the trapezoidal MPA
AUC(0–2h) in comparison with the estimated
AUC(0–8h) or AUC(0–12h) using limited sampling
strategies.
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